The Supreme Court (SC) directed the federal government on Wednesday to launch a nationwide public awareness campaign about breast cancer and heart disease.
The Supreme Court (SC) directed the federal government on Wednesday to launch a nationwide public awareness campaign about breast cancer and heart disease. The case was heard on its own by a three-member bench led by Pakistan’s Chief Justice, Justice Umar Ata Bandial.
At the start of the hearing, the court also directed the additional attorney general to notify the bench after receiving instructions from the federal government regarding the awareness campaign.
Justice Ayesha A. Malik noted that the governments of Balochistan and Sindh had already submitted their reports. She stated that the DRAP was a federal subject and that the government should run an awareness campaign to save people.
According to the Additional Attorney General, the reports from Khyber Pakhtunkhwa and Punjab were still pending. Because the health department was in charge of running this campaign, he asked the court for some time to get instructions from the government.
An awareness campaign about breast cancer and heart disease would involve educating the public about the risk factors, symptoms, and ways to prevent or manage these conditions. This could include distributing informational materials, hosting educational events, and utilizing social media and other forms of advertising to raise awareness.
Additionally, the campaign could work to promote early detection and encourage individuals to schedule regular screenings and check-ups with their healthcare providers. The campaign could also collaborate with local organizations and healthcare providers to provide resources and support for individuals affected by these diseases.
DRAP stands for “Drug Regulatory Authority of Pakistan.” It is a government agency responsible for regulating the pharmaceutical industry in Pakistan, including the registration, import, and sale of drugs.
The main functions of DRAP include ensuring the quality, safety, and efficacy of drugs being sold in Pakistan, monitoring the manufacturing and distribution of drugs, and enforcing compliance with relevant regulations.